Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users
- PMID: 20331553
- PMCID: PMC2857602
- DOI: 10.1111/j.1360-0443.2010.02905.x
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users
Abstract
Aims: Despite proven benefits of antiretroviral therapy (ART), many human immunodeficiency virus (HIV)-infected injection drug users (IDU) do not access treatment even in settings with free health care. We examined whether methadone maintenance therapy (MMT) increased initiation and adherence to ART among an IDU population with free health care.
Design: We examined prospectively a cohort of opioid-using antiretroviral-naive HIV-infected IDU and investigated factors associated with initiation of antiretroviral therapy as well as subsequent adherence. Factors associated independently with time to first initiation of antiretroviral therapy were modelled using Cox proportional hazards regression.
Findings: Between May 1996 and April 2008, 231 antiretroviral-naive HIV-infected opioid-using IDU were enrolled, among whom 152 (65.8%) initiated ART, for an incidence density of 30.5 [95% confidence interval (CI): 25.9-35.6] per 100 person-years. After adjustment for time-updated clinical characteristics and other potential confounders, use of MMT was associated independently with more rapid uptake of antiretroviral therapy [relative hazard = 1.62 (95% CI: 1.15-2.28); P = 0.006]. Those prescribed methadone also had higher rates of ART adherence after first antiretroviral initiation [odds ratio = 1.49 (95% CI: 1.07-2.08); P = 0.019].
Conclusion: These results demonstrate that MMT contributes to more rapid initiation and subsequent adherence to ART among opioid-using HIV-infected IDU. Addressing international barriers to the use and availability of methadone may increase dramatically uptake of HIV treatment among this population.
Figures
Comment in
-
Commentary on Uhlmann et al. (2010): managing HIV in drug users--the huge gap remaining between evidence and international policy and practice.Addiction. 2010 May;105(5):914-5. doi: 10.1111/j.1360-0443.2010.02966.x. Addiction. 2010. PMID: 20402976 No abstract available.
References
-
- Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS. 1996;10:S1–S11. - PubMed
-
- Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568–2577. - PubMed
-
- Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129. - PubMed
-
- Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV-RNA levels during follow-up. J Infect Dis. 2008;197:1145–1155. - PubMed
-
- Hammer SM, Eron JJ, Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
